New Website Addresses Epidermal Growth Factor Receptors in Cancer Therapy
AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on
AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on the latest information and developments concerning epidermal growth factor receptors (EGFRs).
The websiteEGFR-INFO.comis designed for health and medical professionals only and is password protected. This source of comprehensive information on the role of EGFRs in cancer includes the following sections:
A complete guide to EGFRs and cancerincluding the potential role of these receptors in the treatment of cancerillustrated through graphic animations, which can be requested on CD-ROM
A slide library that can be downloaded from the site and will be expanded and updated regularly as more information becomes available
Reports from international medical congresses and netcasts from important satellite symposia
A weekly update on the latest abstracts and information on EGFRs, with hyperlinks to full articles
A section containing the most frequently asked questions, along with the opportunity to submit questions to be answered by leading experts
The opportunity to search the Medline and CancerLit databases
Hyperlinks to a range of EGFR and cancer sites on the Web
Biological Background
Clinical data suggest that excessive levels of EGFR are linked to poor prognosis, including tumor invasion and development of metastases in some types of cancer. Epidermal growth factor receptors are expressed or overexpressed in a variety of common solid tumors, including nonsmall-cell lung cancer, colorectal cancer, ovarian cancer, prostate cancer, and gastric cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
!["[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8987adec8367653dbaf8fc0f82c7dbfcb914281e-500x404.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[G]iven the improvements in compliance and tolerability of the de-escalated regimen in older patients, with preserved early cancer outcomes, this reduced-dose regimen could be considered a new treatment option for [patients who are] frailer [and] not fit for standard-dose chemoradiotherapy,\" according to the study authors.")
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
